283 related articles for article (PubMed ID: 34227051)
1. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
2. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
3. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and management of metastatic pheochromocytoma and paraganglioma].
Jochmanová I; Lazúrová I
Vnitr Lek; 2017; 63(9):580-588. PubMed ID: 29120654
[TBL] [Abstract][Full Text] [Related]
5. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
6. [Pheochromocytoma and paraganglioma: basics for the general practitioner].
Loosli N; Köhler BB; Pechère-Bertschi A; Karenovics W; Triponex F
Rev Med Suisse; 2014 Sep; 10(441):1650-2, 1654-5. PubMed ID: 25322623
[TBL] [Abstract][Full Text] [Related]
7. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
Hamidi O
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):146-154. PubMed ID: 30893083
[TBL] [Abstract][Full Text] [Related]
8. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Gimm O; DeMicco C; Perren A; Giammarile F; Walz MK; Brunaud L
Langenbecks Arch Surg; 2012 Feb; 397(2):155-77. PubMed ID: 22124609
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
[TBL] [Abstract][Full Text] [Related]
10. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
11. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.
Garcia-Carbonero R; Matute Teresa F; Mercader-Cidoncha E; Mitjavila-Casanovas M; Robledo M; Tena I; Alvarez-Escola C; Arístegui M; Bella-Cueto MR; Ferrer-Albiach C; Hanzu FA
Clin Transl Oncol; 2021 Oct; 23(10):1995-2019. PubMed ID: 33959901
[TBL] [Abstract][Full Text] [Related]
13. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
14. Hereditary pheochromocytoma and paraganglioma.
Mazzaglia PJ
J Surg Oncol; 2012 Oct; 106(5):580-5. PubMed ID: 22648936
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome.
Ilias I; Pacak K
Endocr Regul; 2009 Apr; 43(2):89-93. PubMed ID: 19856714
[TBL] [Abstract][Full Text] [Related]
16. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
17. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A in a Cohort of Pheochromocytomas and Paragangliomas: Usefulness at Diagnosis and as an Early Biomarker of Recurrence.
Parisien-La Salle S; Provençal M; Bourdeau I
Endocr Pract; 2021 Apr; 27(4):318-325. PubMed ID: 33581325
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician.
Sharma S; Fishbein L
Endocr Pract; 2023 Dec; 29(12):999-1006. PubMed ID: 37586639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
